Marybeth Sexton

Dr. Marybeth Sexton


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
DADaniel Anderson
Daniel Anderson
BABenjamin Albrecht
Benjamin Albrecht
KJK Ashley Jones
K Ashley Jones
JJJesse T Jacob
Jesse T Jacob
Marybeth SextonMarybeth Sexton
Marybeth Sexton
SSSujit Suchindran
Sujit Suchindran
Extended-spectrum β-lactamase (ESBL)–producing Enterobacterales are frequent causes of urinary tract infections (UTIs). Severe infections caused by ESBL Enterobacterales are often treated with carbapenems, but optimal treatment for less severe infections such as UTIs is unclear. This retrospective cohort study included patients admitted to 4 hospitals in an academic healthcare system with an ESBL UTI treated with either a noncarbapenem β-lactam (NCBL) or a carbapenem for at least 48 hours from 1 April 2014 to 30 April 2018. Those who received an NCBL were compared to those receiving a carbapenem, with a primary outcome of hospital length of stay (LOS) and secondary outcomes of clinical and microbiological response, days until transition to oral therapy, rate of relapsed infection, and rate of secondary infections with a multidrug-resistant organism. Characteristics were similar among patients who received carbapenems (n = 321) and NCBLs (n = 171). There was no difference in LOS for the NCBL group compared to the carbapenem group (13 days vs 15 days, P = .66). The NCBL group had higher rates of microbiologic eradication (98% vs 92%, P = .002), shorter time to transition to oral therapy (5 days vs 9 days, P < .001), shorter overall durations of therapy (7 days vs 10 days, P < .001), and lower rates of relapsed infections (5% vs 42%, P = .0003). Patients treated with NCBLs had similar LOS, higher rates of culture clearance, and shorter durations of antibiotic therapy compared to patients treated with carbapenems, suggesting that treatment for ESBL UTIs should not be selected solely based on phenotypic resistance.

5 February 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
Marybeth SextonMarybeth Sexton
Marybeth Sexton
MKMerin Elizabeth Kuruvilla
Merin Elizabeth Kuruvilla
The selection of perioperative antibiotic prophylaxis is challenging in patients with a history of penicillin allergy; as such, we present a literature review exploring current best practices and the associated supporting evidence, as well as areas for future research. Guidelines recommend the use of alternative agents in patients with an IgE-mediated hypersensitivity reaction, but those alternative agents are associated with worse outcomes, including an increased risk of surgical site infection, and higher cost. More recent data suggest that the risk of cross-reactivity between penicillins and cephalosporins, particularly cefazolin, is extremely low, and that cefazolin can be used safely in most penicillin-allergic patients. Studies have therefore explored how best to implement first-line cefazolin use in patients with a penicillin allergy label. A variety of interventions, including preoperative allergy de-labeling with incorporation of penicillin skin testing, use of patient risk-stratification questionnaires, and utilization of clinician algorithms to guide antibiotic selection intraoperatively, have all been shown to significantly increase cefazolin utilization without a corresponding increase in adverse events. Further studies are needed to clarify the most effective interventions and implementation strategies, as well as to evaluate whether patients with severe delayed hypersensitivity reactions to penicillin should continue to be excluded from receipt of other beta-lactams.

16 August 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
Marybeth SextonMarybeth Sexton
Marybeth Sexton
MKMerin Elizabeth Kuruvilla
Merin Elizabeth Kuruvilla
FWFrancis A. Wolf
Francis A. Wolf
GLGrant C. Lynde
Grant C. Lynde
ZWZanthia Wiley
Zanthia Wiley
Objective: To evaluate whether a series of quality improvement interventions to promote safe perioperative use of cephalosporins in penicillin-allergic patients improved use of first-line antibiotics and decreased costs.Design: Before-and-after trial following several educational interventions.Setting: Academic medical center.Patients: This study included patients undergoing a surgical procedure involving receipt of a perioperative antibiotic other than a penicillin or carbapenem between January 1, 2017, and August 31, 2019. Patients with and without a penicillin allergy label in their electronic medical record were compared with respect to the percentage who received a cephalosporin and average antibiotic cost per patient.Methods: A multidisciplinary team from infectious diseases, allergy, anesthesiology, surgery, and pharmacy surveyed anesthesiology providers about their use of perioperative cephalosporins in penicillin-allergic patients. Using findings from that survey, the team designed a decision-support algorithm for safe utilization and provided 2 educational forums to introduce this algorithm, emphasizing the safety of cefazolin or cefuroxime in penicillin-allergic patients without history of a severe delayed hypersensitivity reaction.Results: The percentage of penicillin-allergic patients receiving a perioperative cephalosporin improved from ∼34% to >80% following algorithm implementation and the associated educational interventions. This increase in cephalosporin use was associated with a ∼50% reduction in antibiotic cost per penicillin-allergic patient. No significant adverse reactions were reported.Conclusions: An educational antibiotic stewardship intervention produced a significant change in clinician behavior. A simple intervention can have a significant impact, although further study is needed regarding whether this response is sustained and whether an educational intervention is similarly effective in other healthcare systems.

14 May 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
KVKristine Vanijcharoenkarn
Kristine Vanijcharoenkarn
FLFrances Eun-Hyung Lee
Frances Eun-Hyung Lee
LMLindsay Martin
Lindsay Martin
JSJennifer Shih
Jennifer Shih
Marybeth SextonMarybeth Sexton
Marybeth Sexton
MKMerin Elizabeth Kuruvilla
Merin Elizabeth Kuruvilla
Addressing coronavirus disease 2019 (COVID-19) vaccine hesitancy and minimizing potential vaccine contraindications are critical to combatting the pandemic. We describe a practical approach to immediate adverse events after the first dose of messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2, focusing on diagnosis and management of allergic reactions.

1 August 2022 in American Journal of Infection Control
Verified
Journal Article
Closed access
Marybeth SextonMarybeth Sexton
Marybeth Sexton
CBChristopher Bower
Christopher Bower
JJJesse T. Jacob
Jesse T. Jacob

9 March 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
RSRoslyn Seitz
Roslyn Seitz
ZWZanthia Wiley
Zanthia Wiley
CFChristele F. Francois
Christele F. Francois
TMTim P. Moran
Tim P. Moran
JRJonathan Rupp
Jonathan Rupp
Marybeth SextonMarybeth Sexton
Marybeth Sexton